These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 35991547)

  • 1. Pan-cancer analyses confirmed the cuproptosis-related gene FDX1 as an immunotherapy predictor and prognostic biomarker.
    Zhang C; Zeng Y; Guo X; Shen H; Zhang J; Wang K; Ji M; Huang S
    Front Genet; 2022; 13():923737. PubMed ID: 35991547
    [No Abstract]   [Full Text] [Related]  

  • 2. Multi-omics pan-cancer study of cuproptosis core gene
    Xu J; Hu Z; Cao H; Zhang H; Luo P; Zhang J; Wang X; Cheng Q; Li J
    Front Immunol; 2022; 13():981764. PubMed ID: 36605188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pan-cancer integrated bioinformatics analysis reveals cuproptosis related gene FDX1 is a potential prognostic and immunotherapeutic biomarker for lower-grade gliomas.
    Huang W; Wu Y; Zhu J; Luo N; Wang C; Liu S; Cheng Z
    Front Mol Biosci; 2023; 10():963639. PubMed ID: 36825202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cuproptosis key gene FDX1 is a prognostic biomarker and associated with immune infiltration in glioma.
    Lu H; Zhou L; Zhang B; Xie Y; Yang H; Wang Z
    Front Med (Lausanne); 2022; 9():939776. PubMed ID: 36523779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cuproptosis-related gene FDX1 as a prognostic biomarker for kidney renal clear cell carcinoma correlates with immune checkpoints and immune cell infiltration.
    Yao Y; Chen H; Lou M; Chen T
    Front Genet; 2023; 14():1071694. PubMed ID: 36755576
    [No Abstract]   [Full Text] [Related]  

  • 6. Spindle component 25 predicts the prognosis and the immunotherapy response of cancers: a pan-cancer analysis.
    Xia F; Yang H; Wu H; Zhao B
    Sci Rep; 2024 Apr; 14(1):8452. PubMed ID: 38605119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ferredoxin 1 is a cuproptosis-key gene responsible for tumor immunity and drug sensitivity: A pan-cancer analysis.
    Yang L; Zhang Y; Wang Y; Jiang P; Liu F; Feng N
    Front Pharmacol; 2022; 13():938134. PubMed ID: 36210836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the functional effects of ferredoxin 1 as a cuproptosis biomarker in cancer.
    Li X; Dai Z; Liu J; Sun Z; Li N; Jiao G; Cao H
    Front Genet; 2022; 13():969856. PubMed ID: 36226187
    [No Abstract]   [Full Text] [Related]  

  • 9. A Novel Cuproptosis-Related Prognostic Model and the Hub Gene
    Zhang K; Yang W; Zhang Z; Ma K; Li L; Xu Y; Qiu J; Yu C; Zhou J; Cai L; Gong Y; Gong K
    J Oncol; 2022; 2022():2124088. PubMed ID: 36536785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comprehensive analysis and validation of cuproptosis-associated genes across cancers: Overall survival, the tumor microenvironment, stemness scores, and drug sensitivity.
    Liu J; Lu Y; Dai Y; Shen Y; Zeng C; Liu X; Yu H; Deng J; Lu W
    Front Genet; 2022; 13():939956. PubMed ID: 36105090
    [No Abstract]   [Full Text] [Related]  

  • 11. Prognostic and immunological role of cuproptosis-related protein FDX1 in pan-cancer.
    Xiao C; Yang L; Jin L; Lin W; Zhang F; Huang S; Huang Z
    Front Genet; 2022; 13():962028. PubMed ID: 36061184
    [No Abstract]   [Full Text] [Related]  

  • 12. Systematic analysis based on the cuproptosis-related genes identifies ferredoxin 1 as an immune regulator and therapeutic target for glioblastoma.
    Dai L; Zhou P; Lyu L; Jiang S
    BMC Cancer; 2023 Dec; 23(1):1249. PubMed ID: 38114959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pan-cancer genetic analysis of cuproptosis and copper metabolism-related gene set.
    Liu H; Tang T
    Front Oncol; 2022; 12():952290. PubMed ID: 36276096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Oncogenic Role of FDX1 in Human Melanoma Related to PD-L1 Immune Checkpoint.
    Lu H; Liang J; He X; Ye H; Ruan C; Shao H; Zhang R; Li Y
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor cuproptosis and immune infiltration improve survival of patients with hepatocellular carcinoma with a high expression of ferredoxin 1.
    Quan Y; Li W; Yan R; Cheng J; Xu H; Chen L
    Front Oncol; 2023; 13():1168769. PubMed ID: 37361595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic and immunological role of FDX1 in pan-cancer: an in-silico analysis.
    Liu Z; Miao J
    Sci Rep; 2023 May; 13(1):7926. PubMed ID: 37193786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cuproptosis-related gene UBE2D2 functions as an immunotherapeutic and prognostic biomarker in pan-cancer.
    Fei Y; Cao D; Dong R; Li Y; Wang Z; Gao P; Zhu M; Wang X; Zuo X; Cai J
    Clin Transl Oncol; 2024 May; ():. PubMed ID: 38703335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive analyses of cuproptosis-related gene CDKN2A on prognosis and immunologic therapy in human tumors.
    Zhang D; Wang T; Zhou Y; Zhang X
    Medicine (Baltimore); 2023 Apr; 102(14):e33468. PubMed ID: 37026918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cuproptosis-related gene
    Wang T; Liu Y; Li Q; Luo Y; Liu D; Li B
    Front Immunol; 2022; 13():999823. PubMed ID: 36225932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.